Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
More Than 600 Patients Now Dosed In Pivotal Phase III Trial
Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.
You may also be interested in...
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
Mylan is teaming up with Israeli firm Mapi Pharma to develop and commercialise a long-acting glatiramer acetate product, Mapi’s ‘GA Depot’ candidate. Subject to approval from the Israeli Innovation Authority, the partnership sees Mylan acquire global marketing rights for the once-monthly injection for treating relapsingremitting multiple sclerosis (RRMS).
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.